RESPINOR's DXT is a novel, non-invasive ultrasound-based medical device. Applicable in critical care for accurate and continuous diaphragm monitoring, for early detection of diaphragm dysfunction. Secured substantial funding from H2020 and The Research Council of Norway. EN ISO 13485:2016 certified. Successfully completed clinical evidence studies for the first patient segment, mechanical ventilation (MV). Working towards regulatory submission in both EU and the US. DXT offers a huge market potential with >350m patients in US/EU. Our vision is to make diaphragm monitoring the next vital sign for assessing work of breathing.
DXT, or Diaphragm Excursion Technology, is a groundbreaking non-invasive medical device developed by RESPINOR that utilizes ultrasound for continuous monitoring of the diaphragm, the main breathing muscle, in critically ill patients. This technology aids in the early detection of diaphragm dysfunction and enhances clinical decision-making in critical care settings.